|
CASP8AP2 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 3.09819947474921E-10 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
6.82059999590479E-08 |
| Normal-vs-Stage2 |
5.18759999956764E-07 |
| Normal-vs-Stage3 |
4.31500000175333E-08 |
| Normal-vs-Stage4 |
1.57300000025451E-07 |
| Stage1-vs-Stage2 |
1.634620E-01 |
| Stage1-vs-Stage3 |
2.597400E-01 |
| Stage1-vs-Stage4 |
1.581210E-01 |
| Stage2-vs-Stage3 |
6.024600E-01 |
| Stage2-vs-Stage4 |
8.016200E-01 |
| Stage3-vs-Stage4 |
7.558800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.11359998999916E-09 |
| Normal-vs-AfricanAmerican |
5.264600E-03 |
| Normal-vs-Asian |
2.013600E-04 |
| Caucasian-vs-AfricanAmerican |
4.306000E-01 |
| Caucasian-vs-Asian |
4.637800E-01 |
| AfricanAmerican-vs-Asian |
8.377800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.53279952566743E-10 |
| Normal-vs-Female |
1.06780000397322E-08 |
| Male-vs-Female |
1.068560E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.7790000000083E-06 |
| Normal-vs-Age(41-60Yrs) |
7.7962003519616E-10 |
| Normal-vs-Age(61-80Yrs) |
2.45090000516868E-08 |
| Normal-vs-Age(81-100Yrs) |
1.657300E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
8.843800E-02 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.097560E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
1.962810E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
8.256800E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
3.986600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
4.542600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
6.069200E-01 |
| Classical-VS-Follicular |
1.462640E-03 |
| Classical-VS-Other |
3.667800E-01 |
| Classical-VS-Normal |
1.45220000025148E-07 |
| Tall-VS-Follicular |
1.641190E-01 |
| Tall-VS-Other |
5.492800E-01 |
| Tall-VS-Normal |
4.966900E-04 |
| Follicular-VS-Other |
8.752200E-01 |
| Follicular-VS-Normal |
1.46459999683657E-09 |
| Other-VS-Normal |
1.371620E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.2786994513524E-10 |
| Normal-vs-N1 |
2.80149999998258E-06 |
| N0-vs-N1 |
6.957800E-01 |
|
|
